Search Results - stephen+leppla

16 Results

Sort By:

Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule

B. anthracis strains BH480; plasmids encoding anthrax edema factor (EF) variants pSJ136EFOS, pSJ 136EFA and pSJ 136EFR.

Published: 7/25/2024 | Inventor(s): Clinton Leysath, Stephen Leppla

Keywords(s): ADENYLATE, Are, CYCLASE, DD1XXX, Dependent, Edema, factor, Having, Highly, Highlydependent, Listed LPM Soukas as of 4/15/2015, N-END, Post LPM Assignment Set 20150420, Potencies, Pre LPM working set 20150418, RM, RULE, That, VARIANTS, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease

Expression, Purification, and Validation of Anthrax Toxin Proteins

Expression, purification, and validation of anthrax toxin proteins.

Published: 7/25/2024 | Inventor(s): Rasem Fattah, Stephen Leppla

Keywords(s): Anthrax, Expression, proteins, purification, RM, toxin, Validation, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA. Protective antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA...

Published: 7/25/2024 | Inventor(s): Stephen Leppla

Keywords(s): Acid, AMINO, Anthrax, ANTIGEN, Edema, factor, Lethal, Listed LPM Ano as of 4/15/2015, Mutants, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, RM, SUBSTITUTIONS, VJXXXX, WIXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials

Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique...

Published: 7/25/2024 | Inventor(s): Larry Lantz, David Garboczi, Damilola Phillips, Clinton Leysath, Stephen Leppla

Keywords(s): 89.6, Antibod, DDXXXX, DNA/RNA, HYBRIDS, Listed LPM Ano as of 4/15/2015, MANNER, monoclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Recognizes, S9.6, Sequence-independent

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials

Plasmids Encoding and Producing Anthrax Toxin Proteins

Plasmid pSJ136-EF-A — A plasmid encoding mutant anthrax toxin proteins such as lethal factor (LF) or edema factor (EF). Anthrax toxin and anthrax toxin fusion proteins may be used as therapeutic agents for cancer. Plasmid PSJ115-LFOS — A plasmid expressing anthrax toxin proteins such as lethal factor (LF) or edema factor (EF) which has the original...

Published: 7/25/2024 | Inventor(s): Pradeep Gupta, Yiu Cheung, Haijing Hu, Mahtab Moayeri, Stephen Leppla

Keywords(s): Anthrax, Improved, Listed LPM Soukas as of 4/15/2015, Methods, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, proteins, RM, TOXINS, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu

Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Christopher Bachran, Stephen Leppla

Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Engineered Anthrax Toxin Variants that Target Cancer

This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath

Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Andrei Pomerantsev

Keywords(s): Anthracis, Anthrax, ATCC, Bacillus, Bacterial, BH460, DB3XXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, HOST, Improved, production, proteins, toxin, vaccines

Category(s): Collaboration Sought > Collaboration, Application > Vaccines, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease

1 2